UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Jasper Therapeutics, Inc.
(Name of Issuer)
Voting Common Stock, $0.0001 par value per share
(Title of Class of Securities)
471871 103
(CUSIP Number)
January 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 471871 103 |
| 1) |
Names of reporting persons.
AMGEN INC. | |||||
| 2) | Check the appropriate box if a member of a group (see instructions)
(a) ☐ (b) ☐ | |||||
| 3) | SEC use only
| |||||
| 4) | Citizenship or place of organization
Delaware | |||||
| Number of shares beneficially owned by each reporting person with: |
5. | Sole voting power
1,009,929 | ||||
| 6. | Shared voting power
0 | |||||
| 7. | Sole dispositive power
1,009,929 | |||||
| 8. | Shared dispositive power
0 | |||||
| 9) |
Aggregate amount beneficially owned by each reporting person
1,009,929 | |||||
| 10) | Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
☐ | |||||
| 11) | Percent of class represented by amount in Item 9
0.9%(1) | |||||
| 12) | Type of reporting person (see instructions)
CO | |||||
| (1) | Based on 100,321,864 shares of the Issuer’s Common Stock outstanding as of January 27, 2023, after giving effect to the issuance of 69,000,000 shares of Common Stock pursuant to the closing of the Issuer’s underwritten public offering of shares, as disclosed in the prospectus supplement that was filed by the Issuer with the Securities and Exchange Commission on January 25, 2023 and in the Issuer’s Current Report on Form 8-K filed on January 27, 2023. |
ITEM 1.
(A) NAME OF ISSUER:
Jasper Therapeutics, Inc. (the “Issuer”)
(B) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICE:
2200 Bridge Pkwy Suite #102
Redwood City, CA 94065
ITEM 2.
(A) NAME OF PERSON FILING:
Amgen Inc.
(B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
One Amgen Center Drive, Thousand Oaks, California 91320-1799
(C) CITIZENSHIP:
Delaware, U.S.A.
(D) TITLE OF CLASS OF SECURITIES:
Common Stock, $0.0001 par value per share
(E) CUSIP NUMBER:
471871 103
ITEM 3. STATEMENT FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B) OR (C)
Not applicable.
ITEM 4. OWNERSHIP.
(a), (b) and (c)—The information contained on the cover page to this Schedule 13G is incorporated herein by reference.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
ITEM 10. CERTIFICATION.
Not applicable.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 10, 2023
| AMGEN INC. | ||
| By: | /s/ Rachna Khosla | |
| Name: | Rachna Khosla | |
| Title: | Senior Vice President, Business Development | |